A Phase 4 interventional study of Doxycycline and Metronidazole in Rosacea, sponsored by Galderma R&D. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-01.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.
Among the 12 studies testing doxycycline in Rosacea, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 4, and was the 6th registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2011.
This study's enrollment of 235 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 150 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2011, is one of 9 in phase 4, and was the 14th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
1 of the studies testing doxycycline in Rosacea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.
Adult subjects with moderate to severe papulopustular rosacea will receive Oracea® and MetroGel® 1% once daily during phase 1 (baseline to week 12) of the study. Subjects will be eligible to enter phase 2 of the study based upon improvements in the Investigator's Global Assessment (IGA) score. During phase 2, subjects will receive either Oracea® or placebo once daily for up to an additional 40 weeks. Subjects who relapse during phase 2 will be discontinued from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive placebo during phase 2 (week 12 - week 52)
Drug: Placebo
Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
Drug: Doxycycline · Drug: Metronidazole
Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
Drug: Doxycycline
During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
Also known as: Oracea® Capsules 40 mg
During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
Also known as: Metrogel 1%
During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
Period 2: Number of Subjects Who Relapsed
Subjects who relapsed during phase 2 were discontinued. Relapse was defined as meeting any one of the following criteria: * A return to the baseline lesion count * A return to the baseline IGA score * The investigator determines that a change in rosacea treatment is warranted due to the subject's clinical condition. The numbers reported here are accumulative numbers for each arm.
Time frame: Period 2 (40 weeks)
Period 2: Investigator's Global Assessment Success
The evaluator (investigator) assessed the severity of rosacea at baseline and each postbaseline visit using a 5 point Investigator's Global Assessment scale. Subjects scores were then dichotomized into success (clear or near clear score) or failure (mild, moderate, or severe score).
Time frame: Period 2 (40 weeks)
Period 2: Clinician's Erythema Assessment
The evaluator (investigator) assessed the severity of erythema at baseline and each postbaseline visit using a total erythema score. The erythema of 5 areas of the face (forehead, chin, nose, right cheek, left cheek) was scored using a 5 point Clinician's Erythema Assessment scale (0 = none, 1 = mild, 2 = moderate, 3 = significant, 4 = severe). The total of the 5 individual erythema scores scores was the total erythema score.
Time frame: Period 2 (40 Weeks)
Period 2: Inflammatory Lesion Count
The evaluator (investigator or a designee) performed lesion counts at each postbaseline visit.
Time frame: Period 2 (40 Weeks)
Period 1: Tolerability (Scaling)
Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.
Time frame: Period 1 (12 Weeks)
Period 1: Tolerability (Stinging/Burning)
Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.
Time frame: Period 1 (12 Weeks)
Period 1: Tolerability (Dryness)
Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.
Time frame: Period 1 (12 Weeks)
| Milestone | Doxycycline and Metronidazole Regimen | Oral Doxycycline | Placebo |
|---|---|---|---|
| Started | 235 | 0 | 0 |
| Completed | 180 | 0 | 0 |
| Not completed | 55 | 0 | 0 |
| Withdrew: Adverse event | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 22 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 22 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Milestone | Doxycycline and Metronidazole Regimen | Oral Doxycycline | Placebo |
|---|---|---|---|
| Started | 180 | 0 | 0 |
| Completed | 130 | 0 | 0 |
| Not completed | 50 | 0 | 0 |
| Withdrew: Did not qualify | 42 | 0 | 0 |
| Withdrew: Qualified, opted out | 8 | 0 | 0 |
| Milestone | Doxycycline and Metronidazole Regimen | Oral Doxycycline | Placebo |
|---|---|---|---|
| Started | 0 | 65 | 65 |
| Completed | 0 | 27 | 18 |
| Not completed | 0 | 38 | 47 |
| Withdrew: Adverse event | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 9 | 11 |
| Withdrew: Protocol violation | 0 | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 8 | 6 |
| Withdrew: Site closed | 0 | 6 | 5 |
| Withdrew: Relapsed | 0 | 9 | 18 |
Subjects who relapsed during phase 2 were discontinued. Relapse was defined as meeting any one of the following criteria: * A return to the baseline lesion count * A return to the baseline IGA score * The investigator determines that a change in rosacea treatment is warranted due to the subject's clinical condition. The numbers reported here are accumulative numbers for each arm.
| participants | Oral Doxycycline | Placebo |
|---|---|---|
| Week 4 | 4 | 10 |
| Week 8 | 8 | 14 |
| Week 12 | 9 | 16 |
| Week 16 | 9 | 16 |
| Week 20 | 9 | 16 |
| Week 24 | 9 | 17 |
| Week 28 | 9 | 18 |
| Week 32 | 9 | 18 |
| Week 36 | 9 | 18 |
| Week 40 | 9 | 18 |
The evaluator (investigator) assessed the severity of rosacea at baseline and each postbaseline visit using a 5 point Investigator's Global Assessment scale. Subjects scores were then dichotomized into success (clear or near clear score) or failure (mild, moderate, or severe score).
| participants | Oral Doxycycline | Placebo |
|---|---|---|
| Week 4 | 44 | 38 |
| Week 8 | 36 | 33 |
| Week 12 | 33 | 37 |
| Week 16 | 38 | 34 |
| Week 20 | 35 | 33 |
| Week 24 | 36 | 32 |
| Week 28 | 39 | 35 |
| Week 32 | 39 | 34 |
| Week 36 | 40 | 33 |
| Week 40 | 41 | 33 |
The evaluator (investigator) assessed the severity of erythema at baseline and each postbaseline visit using a total erythema score. The erythema of 5 areas of the face (forehead, chin, nose, right cheek, left cheek) was scored using a 5 point Clinician's Erythema Assessment scale (0 = none, 1 = mild, 2 = moderate, 3 = significant, 4 = severe). The total of the 5 individual erythema scores scores was the total erythema score.
| units on a scale | Oral Doxycycline | Placebo |
|---|---|---|
| Week 4 | 5.0 ± 3.1 | 5.6 ± 3.8 |
| Week 8 | 4.9 ± 3.5 | 5.8 ± 3.9 |
| Week 12 | 4.7 ± 3.4 | 5.3 ± 4.3 |
| Week 16 | 4.7 ± 3.4 | 5.2 ± 3.8 |
| Week 20 | 4.3 ± 3.4 | 5.5 ± 3.8 |
| Week 24 | 4.4 ± 3.5 | 5.3 ± 3.8 |
| Week 28 | 4.3 ± 3.5 | 5.3 ± 3.8 |
| Week 32 | 4.2 ± 3.6 | 5.3 ± 3.9 |
| Week 36 | 4.4 ± 3.6 | 5.3 ± 3.8 |
| Week 40 | 4.4 ± 3.5 | 5.3 ± 3.9 |
The evaluator (investigator or a designee) performed lesion counts at each postbaseline visit.
| lesions | Oral Doxycycline | Placebo |
|---|---|---|
| Week 4 | 2.8 ± 4.5 | 5.8 ± 8.7 |
| Week 8 | 3.1 ± 4.1 | 4.3 ± 6.0 |
| Week 12 | 3.0 ± 4.2 | 1.9 ± 2.7 |
| Week 16 | 2.4 ± 4.0 | 2.3 ± 2.6 |
| Week 20 | 2.1 ± 2.2 | 2.6 ± 3.1 |
| Week 24 | 2.2 ± 2.7 | 2.9 ± 3.9 |
| Week 28 | 2.2 ± 2.8 | 2.9 ± 4.0 |
| Week 32 | 2.2 ± 3.0 | 2.4 ± 3.3 |
| Week 36 | 2.5 ± 3.1 | 2.2 ± 3.0 |
| Week 40 | 2.1 ± 2.6 | 1.6 ± 1.9 |
Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.
| participants | Baseline | Week 4 | Week 8 | Week 12 |
|---|---|---|---|---|
| None | 103 | 136 | 139 | 143 |
| Mild | 85 | 58 | 44 | 23 |
| Moderate | 44 | 24 | 11 | 2 |
| Severe | 3 | 0 | 0 | 0 |
| Missing | 0 | 17 | 41 | 67 |
Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.
| participants | Baseline | Week 4 | Week 8 | Week 12 |
|---|---|---|---|---|
| None | 90 | 135 | 139 | 143 |
| Mild | 71 | 51 | 44 | 19 |
| Moderate | 60 | 31 | 11 | 6 |
| Severe | 14 | 1 | 0 | 0 |
| Missing | 0 | 17 | 41 | 67 |
Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.
| participants | Baseline | Week 4 | Week 8 | Week 12 |
|---|---|---|---|---|
| None | 76 | 106 | 120 | 125 |
| Mild | 89 | 78 | 61 | 37 |
| Moderate | 60 | 32 | 13 | 6 |
| Severe | 10 | 2 | 0 | 0 |
| Missing | 0 | 17 | 41 | 67 |
Collected over Period 1 (12 weeks of treatment with oral doxycycline and topical metronidazole) and Period 2 (40 weeks of treatment with oral doxycycline or placebo). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Oral Doxycycline and Topical Metronidazole | — | 4/235 (1.7%) | 9/235 (3.8%) |
| Period 2: Oral Doxycycline | — | 2/65 (3.1%) | 6/65 (9.2%) |
| Period 2: Placebo | — | 2/65 (3.1%) | 7/65 (10.8%) |
| Event | Period 1: Oral Doxycycline and Topical Metronidazole | Period 2: Oral Doxycycline | Period 2: Placebo |
|---|---|---|---|
| CellulitisInfections and infestations | 0/235 | 1/65 | 0/65 |
| Infected bitesInfections and infestations | 0/235 | 1/65 | 0/65 |
| GastritisGastrointestinal disorders | 0/235 | 1/65 | 0/65 |
| PresyncopeNervous system disorders | 0/235 | 1/65 | 0/65 |
| Grand mal convulsionNervous system disorders | 0/235 | 0/65 | 1/65 |
| Endometrial cancer stage 1Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/235 | 0/65 | 1/65 |
| DiverticulitisInfections and infestations | 1/235 | 0/65 | 0/65 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/235 | 0/65 | 0/65 |
| HeadacheNervous system disorders | 1/235 | 0/65 | 0/65 |
| ThyroidectomySurgical and medical procedures | 1/235 | 0/65 | 0/65 |
| Event | Period 1: Oral Doxycycline and Topical Metronidazole | Period 2: Oral Doxycycline | Period 2: Placebo |
|---|---|---|---|
| Upper respiratoryInfections and infestations | 1/235 | 1/65 | 3/65 |
| NauseaGastrointestinal disorders | 2/235 | 2/65 | 0/65 |
| Gastroenteritis viralInfections and infestations | 1/235 | 2/65 | 0/65 |
| SinusitisInfections and infestations | 4/235 | 1/65 | 2/65 |
| Actinic keratosisSkin and subcutaneous tissue disorders | 1/235 | 0/65 | 2/65 |
The safety population included 235 enrolled subjects. However, Baseline demographics were based on the ITT population which included 230 subjects; 5 subjects were excluded from this population due to consent issues.
| Age, Continuous(years) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| Mean | 47.4 ± 12.9 |
| Sex: Female, Male(Participants) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| Female | 164 |
| Male | 66 |
| Race (NIH/OMB)(Participants) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 217 |
| More than one race | 5 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| Hispanic or Latino | 44 |
| Not Hispanic or Latino | 186 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| United States | 230 |
| Skin Type(participants) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| Dry | 40 |
| Normal | 50 |
| Oily | 38 |
| Combination | 102 |
| FItzpatrick Skin Type(participants) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| I | 16 |
| II | 93 |
| III | 64 |
| IV | 42 |
| V | 15 |
| VI | 0 |
| History of Rosacea(years) | Period 1: Oral Doxycycline and Topical Metronidazole |
|---|---|
| Mean | 4.4 ± 7.7 |
2 further baseline measures are reported on the registry.
The record gives a start of Sep 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doxycycline · Metronidazole